Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures

Colonoscopy Clinical Trial

Official title:

Effect of Lactulose and/ or Polyethylene Glycol Solution for Bowel Preparation in Colonscopy: a Multi-center Prospective Randomized Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05076799
• Other study ID #: Sichuan U
• Status: Completed
• Phase: Phase 3
• Start date: September 1, 2021
• Est. completion date: November 30, 2022

Study information

• Verified date: December 2022
• Source: Sichuan University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Colonoscopy is the most useful exam used to evaluate colorectal diseases, like colorectal polyps and cancer. The appropriate bowel preparation is indispensable for colonoscopy procedures. Polyethylene glycol solution (PEG) is the most frequent laxative medication. However, the taste is poor, and patients need to drink a lot of liquids to obtain adequate visualization of the mucosal surface. In fact, no laxative has all the characteristics of an ideal medication. Lactulose is an osmotic laxative which widely used in cirrhosis and constipation patients, and could inhibit bacterial in the colon to increase colon cleanliness and prolong the effect time of PEG. Previous study demonstrate PEG combined with lactulose has a significant improvement in the quality of bowel preparation compared with PEG alone. The present study aim to assess the efficacy of lactulose with or without PEG in bowel preparation to improve mucosal visualization, reduced volume of fluid consumed, and preparation intolerance.

Description:

This study will conduct in 5 clinical central. 1000 participants who were scheduled for colonoscopy age between 18 and 80 years were enrolled in the study. Exclusion criteria were patients with uncontrolled acute or recurrent chronic intestinal infections, with active gastrointestinal bleeding or gastrointestinal stricture or intestinal obstruction, with severity coronary heart disease or heart failure or renal failure and liver failure or severe electrolyte metabolism disorder, with pregnant or lactating or metal diseases or refuse to colonoscopy examination. Central stratification and block randomization is achieved via a computer-generated random-sequence table by using R software. The participants will be assigned into one of four groups at a ratio of 1 : 1, and received a single 3 L dose of either PEG or 200ml dose of lactulose, 100ml lactulose combined with 1L PEG, 100ml lactulose combined with 2L PEG. The following parameters were then obtained: time of the first defecation, defecation frequency, the overall drink liquid volume, the taste of the preparation, the tolerance evaluation, the cleansing quality of the bowel preparations and adverse reaction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: November 30, 2022
• Est. primary completion date: November 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Participants who were scheduled for colonoscopy age between 18 and 80 years

Exclusion Criteria:

• uncontrolled acute or recurrent chronic intestinal infections

• active gastrointestinal bleeding, gastrointestinal stricture, intestinal obstruction

• severe electrolyte metabolism disorder, severe coronary heart disease, heart failure, renal failure or liver failure

• pregnant, lactating, have metal diseases or refuse to colonoscopy examination

Related Conditions & MeSH terms

• Colonoscopy

Intervention

Drug:
• 100 ml lactulose combined with 1 L PEG
the participants were instructed to consume 100 ml lactulose combined with 1000 mL of PEG solution
• 100 ml lactulose combined with 2 L PEG
the participants were instructed to consume 100 ml lactulose combined with 2000 mL of PEG solution
• 200 ml lactulose
the participants were instructed to consume 200 ml lactulose alone
• 3 L Polyethylene glycol solution
the participants were instructed to consume 3000 mL of PEG solution

Locations

Country	Name	City	State
China	west china fourth hospital of Sichuan university	Chendu	Sichuan

Sponsors (3)

Lead Sponsor	Collaborator
Sichuan University	Af?liated Hospital of North Sichuan Medical College, Affiliated Hospital of Southwest Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The quality of bowel preparation	to assess the quality of bowel preparation by using Boston Bowel Preparation Scale. The minimum score value is 0,and the maximum value is 9. A higher score means a better outcome. Bowel cleansing was scored by the endoscopist performing the colonoscopy in the single-blind method.	up to 12 months
Primary	The preparation intolerance	to assess the preparation intolerance including the palatability of the bowel-cleansing agents, the general satisfaction with the bowel preparation, the willingness to perform another colonoscopy by using case report questionnaire. Moreover, the ratio of drink all preparation fluids and the specific amount of bowel preparation fluid are documented.	up to 12 months
Secondary	The colorectal diseases detection rate	the cecal intubation time, colonoscopy perform time, and polyp detection rate or colorectal cancer detection rate are recorded.	up to 12 months
Secondary	The adverse events	the adverse events including nausea, vomiting, abdominal pain, abdominal distension, and other adverse reactions after administration are evaluated.	up to 12 months